We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Travere (TVTX) Surges 11.6%: Is This an Indication of Further Gains?
Read MoreHide Full Article
Travere Therapeutics (TVTX - Free Report) shares soared 11.6% in the last trading session to close at $15.23. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 37.5% gain over the past four weeks.
Last month, the FDA granted full approval to the company’s marketed product, Filspari (sparsentan), an oral non-immunosuppressive drug, for treating primary IgA nephropathy (IgAN) in adults who stand at high/low risk of disease progression. The approval made Filspari the only non-immunosuppressive drug available for this condition. This might have driven the recent share price rally.
This drug developer is expected to post quarterly loss of $0.71 per share in its upcoming report, which represents a year-over-year change of +39.3%. Revenues are expected to be $59.42 million, up 60.2% from the year-ago quarter.
While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For Travere, the consensus EPS estimate for the quarter has been revised 1.8% higher over the last 30 days to the current level. And a positive trend in earnings estimate revision usually translates into price appreciation. So, make sure to keep an eye on TVTX going forward to see if this recent jump can turn into more strength down the road.
Travere belongs to the Zacks Medical - Biomedical and Genetics industry. Another stock from the same industry, Orchestra BioMed Holdings, Inc. (OBIO - Free Report) , closed the last trading session 1.6% higher at $4.98. Over the past month, OBIO has returned -15.4%.
Orchestra BioMed Holdings, Inc.'s consensus EPS estimate for the upcoming report has remained unchanged over the past month at -$0.44. Compared to the company's year-ago EPS, this represents a change of -15.8%. Orchestra BioMed Holdings, Inc. currently boasts a Zacks Rank of #4 (Sell).
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Travere (TVTX) Surges 11.6%: Is This an Indication of Further Gains?
Travere Therapeutics (TVTX - Free Report) shares soared 11.6% in the last trading session to close at $15.23. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 37.5% gain over the past four weeks.
Last month, the FDA granted full approval to the company’s marketed product, Filspari (sparsentan), an oral non-immunosuppressive drug, for treating primary IgA nephropathy (IgAN) in adults who stand at high/low risk of disease progression. The approval made Filspari the only non-immunosuppressive drug available for this condition. This might have driven the recent share price rally.
This drug developer is expected to post quarterly loss of $0.71 per share in its upcoming report, which represents a year-over-year change of +39.3%. Revenues are expected to be $59.42 million, up 60.2% from the year-ago quarter.
While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For Travere, the consensus EPS estimate for the quarter has been revised 1.8% higher over the last 30 days to the current level. And a positive trend in earnings estimate revision usually translates into price appreciation. So, make sure to keep an eye on TVTX going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Travere belongs to the Zacks Medical - Biomedical and Genetics industry. Another stock from the same industry, Orchestra BioMed Holdings, Inc. (OBIO - Free Report) , closed the last trading session 1.6% higher at $4.98. Over the past month, OBIO has returned -15.4%.
Orchestra BioMed Holdings, Inc.'s consensus EPS estimate for the upcoming report has remained unchanged over the past month at -$0.44. Compared to the company's year-ago EPS, this represents a change of -15.8%. Orchestra BioMed Holdings, Inc. currently boasts a Zacks Rank of #4 (Sell).